Santa Clara, CA, United States of America

Paul Humphries

This inventor holds 8 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Reset Therapeutics, Inc., Centessa Pharmaceuticals (UK) Limited, Synchronicity. Active years: 2016-2026.

USPTO Granted Patents = 8 (Patent Applications = 7)

% Patents Active = 75.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 22(Granted Patents)

Company Filing History:

4 out of 4

Reset Therapeutics, Inc.

patents

2 out of 12

Centessa Pharmaceuticals (UK) Limited

Synchronicity Pharma, Inc.

patent

Years Active: 2016-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679804 - 2-(3-ethynylbenzyl)-substituted heterocycle derivatives and related uses (2026-07-14),

2. 12503475 - Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists (2025-12-23),

3. 10759777 - Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators (2020-09-01),

4. 10383880 - Carbazole-containing sulfonamides as cryptochrome modulators (2019-08-20),

5. 10214507 - Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators (2019-02-26),

6. 10005759 - Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators (2018-06-26),

7. 9775845 - Carbazole-containing sulfonamides as cryptochrome modulators (2017-10-03),

8. 9265772 - Carbazole-containing sulfonamides as cryptochrome modulators (2016-02-23),

Title: The Innovative Contributions of Paul Humphries

Introduction

Paul Humphries is a notable inventor based in Santa Clara, CA. He has made significant contributions to the field of pharmaceuticals, holding a total of 8 patents. His work focuses on developing compounds that have the potential to treat various medical disorders.

Latest Patents

Among his latest patents is a groundbreaking invention related to bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists. This patent discloses compounds that are useful for modulating orexin receptor activity, which may be beneficial in treating disorders such as narcolepsy, neurodegenerative disorders, and metabolic syndromes. Another significant patent involves carbazole-containing amides, carbamates, and ureas as cryptochrome modulators. This invention aims to address Cry-mediated diseases, including diabetes and asthma, by providing pharmaceutical compositions containing these innovative compounds.

Career Highlights

Throughout his career, Paul has worked with various companies, including Reset Therapeutics, Inc. and Centessa Pharmaceuticals (UK) Limited. His expertise in pharmaceutical development has positioned him as a key player in the industry, contributing to advancements in medical treatments.

Collaborations

Paul has collaborated with notable professionals in his field, including Ross Bersot and Karl Gibson. These partnerships have further enhanced his research and development efforts, leading to innovative solutions in healthcare.

Conclusion

Paul Humphries exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations continue to pave the way for advancements in medical treatments.